-
Use of Eliquis and Xarelto After Gastric Banding or Other Weight Loss Surgery
Dr. Stephan Moll writes (last updated: March 25th, 2020)… Question: Can a person who needs to be on a blood thinner and who has had gastric banding or gastric bypass surgery for weight loss be on Eliquis®, Xarelto®, Pradaxa®, or Savaysa®? Answer: Warfarin is currently the preferred choice, because the absorption of the direct oral anticoagulants…
-
Antiphospholipid Syndrome: Can the New Oral Anticoagulants Be Used?
Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin have traditionally been used. A question that comes up is whether one of the new oral anticoagulants (DOACs) can be effectively and safely…
-
ACCP Guideline for DVT and PE Treatment: New Edition, 2016
The ACCP Chest Guidelines have been the main guide over the last more than 2 decades for evidence-based recommendations on best management of anticoagulants for various indications, including DVT and PE. The 10th edition of the chapter on DVT and PE management was published in Jan 2016 [ref 1]. Unfortunately, the guideline is not available for non-subscribers.
-
Warfarin Interruption for Surgery: Bridging with LMWH Often Not Needed
Stephan Moll, MD writes: Interesting and relevant publication today in the New England Journal of Medicine (NEJM)
-
Fourth NOAC FDA Approved for DVT, PE and Atrial Fibrillation: Savaysa (Edoxaban)
Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release is here (link). Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The…
-
Antidotes for the New Oral Anticoagulants: Update
Stephan Moll, MD writes (on Nov 7th, 2014)… A N Engl J Med publication this week [ref 1] reports on a new reversal agent (PER977 = Aripazine = ciraparantag) that may be effective against a number of different new oral anticoagulants.
-
Xarelto Dosing in Obese Patients
Stephan Moll, MD writes… Is there a dose change or limitation for the use of Xarelto® (rivaroxaban) in very obese or underweight patients?
-
Apixaban (Eliquis) FDA-Approval for DVT and PE Treatment
Stephan Moll, MD writes… Apixaban (Eliquis®) was approved by the FDA this week (Aug 21, 2014) for the treatment of DVT and PE. The approval covers (a) acute DVT/PE management and (b) prevention of recurrent DVT/PE.
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 